Bicycle Therapeutics Announces Four Abstracts Accepted for Presentation at the ESMO Congress 2024

On July 22, 2024 Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, reported the acceptance of four abstracts for poster presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2024, taking place September 13-17 in Barcelona (Press release, Bicycle Therapeutics, JUL 22, 2024, View Source [SID1234644999]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:

Title: BT8009 monotherapy in enfortumab vedotin-naïve patients with metastatic urothelial carcinoma (mUC): Updated results of Duravelo-1
Poster Session Title: Poster session 01
Date and Time: Saturday, Sept. 14, at 9-10 a.m. CEST
Presentation Number: 652P
Speaker: Oscar Reig Torras, M.D., Hospital Clinic de Barcelona

Title: Peripheral neuropathy following treatment with Bicycle Toxin Conjugates BT8009 or BT5528 monotherapy in patients with advanced solid tumors
Poster Session Title: Poster session 01
Date and Time: Saturday, Sept. 14, at 9-10 a.m. CEST
Presentation Number: 654P
Speaker: Bernard Doger de Spéville, M.D., Ph.D., START Madrid-FJD and Hospital Universitario Fundacion Jimenez Diaz

Title: EphA2-targeting Bicycle Toxin Conjugate BT5528 in patients with advanced solid tumors: A phase 1/2 study
Poster Session Title: Poster session 01
Date and Time: Saturday, Sept.14, at 9-10 a.m. CEST
Presentation Number: 647P
Speaker: Elisa Fontana, M.D., Ph.D., Sarah Cannon Research Institute UK

Title: Initial results from a phase 1/2 study of BT7480, a novel Nectin-4/CD137 Bicycle Tumor-Targeted Immune Cell Agonist, in patients with advanced solid tumors
Poster Session Title: Poster session 01
Date and Time: Saturday, Sept.14, at 9-10 a.m. CEST
Presentation Number: 650P
Speaker: Kyriakos P. Papadopoulos, M.D., START San Antonio

The posters will be made available in the Publications section of bicycletherapeutics.com following the presentations.